Please upgrade your browser.
Conquer Cancer Foundation of ASCO Honors Researchers for Work in Measuring and Improving the Quality of Cancer Care
Merck is testing ridaforolimus in other cancer types including kidney cancer.
What is the IKCS and why should it matter to patients living with kidney cancer?
Who are you going to believe, him or your lying eyes? During his re-election campaign, President Obama said that his administration has pursued “fraud in Medicare and Medicaid very aggressively—more aggressively than ever before.” America’s seniors deserve to know the truth behind this misleading assertion.
AVEO Oncology, a Cambridge-based cancer therapeutics company, and its Japanese partner Astellas Pharma Inc. said Wednesday that federal regulators have agreed to review its drug candidate for kidney cancer.
Scientists have been trying to figure out how different people have kidney tumours with the same histology, or shape, although the genetic changes can vary among individual tumours.
Doctors 'are withholding treatment from dying cancer patients because they think it is futile to continue'
α-Enolase for postoperative follow up, and galectin-1 and galectin-3 for primary detection
Targeted therapy has become both the centerpiece of the current era in cancer therapeutics and the foundation of the field's hope for future progress. Although the initial successes of targeted therapies occurred in hematologic malignancies, recent years have seen a string of promising results in a number of solid tumors.
Cancer advocate Sarah Wise Miller, a member of the Kidney Cancer Association’s governing board, recently participated in the evaluation of research applications submitted to the Peer Reviewed Cancer Research Program (PRCRP) sponsored by the Department of Defense. Ms. Wise was nominated for participation in the program by the Association.
|Powered by NeonCRM|